

# Appendix 1

Appendix S1. Search strategy in databases

| Database       | Strategy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Number |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| PubMed         | (("Flax"[MeSH Terms] OR "Flax"[Title/Abstract] OR "flax-seed"[Title/Abstract] OR "flax-seed"[Title/Abstract] OR "linseed"[Title/Abstract] OR "lignan"[Title/Abstract] OR "whole flaxseed"[Title/Abstract] OR "ground flaxseed"[Title/Abstract] OR "linseed"[Title/Abstract] OR "Linum usitatissimum"[Title/Abstract] OR "linum"[Title/Abstract] OR "Linseed Oil"[MeSH Terms] OR "flaxseed oil"[Title/Abstract] OR "Linseed Oil"[Title/Abstract] OR "Linum usitatissimum"[Title/Abstract] OR "secoisolariciresinol diglucoside"[Title/Abstract]) AND ("Lipid profile"[Title/Abstract] OR "lipid"[Title/Abstract] OR "lipids"[Title/Abstract] OR "blood lipids"[Title/Abstract] OR "Lipoproteins"[MeSH Terms] OR "Lipoproteins"[Title/Abstract] OR "Lipoprotein"[Title/Abstract] OR "Abetalipoproteinemia"[Title/Abstract] OR "Cholesterol"[MeSH Terms] OR "Cholesterol"[Title/Abstract] OR "Total cholesterol"[Title/Abstract] OR "TC"[Title/Abstract] OR "Hypercholesterolemia"[Title/Abstract] OR "Hypercholesterolemic"[Title/Abstract] OR "high density lipoprotein"[Title/Abstract] OR "HDL"[Title/Abstract] OR "HDL-C"[Title/Abstract] OR "TC/HDL ratio"[Title/Abstract] OR "HDL3"[Title/Abstract] OR "HDL2"[Title/Abstract] OR "IDL"[Title/Abstract] OR "low density lipoprotein"[Title/Abstract] OR "Low Density Lipoprotein Cholesterol"[Title/Abstract] OR "lipoproteins, ldl"[MeSH Terms] OR "LDL"[Title/Abstract] OR "LDL Cholesterol"[Title/Abstract] OR "LDL-C"[Title/Abstract] OR "cholesterol ldl"[Title/Abstract] OR "VLDL"[Title/Abstract] OR "triglyceride"[Title/Abstract] OR "Triglycerides"[Title/Abstract] OR "TG"[Title/Abstract] OR "Triacylglycerol"[Title/Abstract] OR "TAG"[Title/Abstract] OR "Hyperlipidemias"[Title/Abstract] OR "Hyperlipidemic"[Title/Abstract] OR "Triglycerides"[MeSH Terms] OR "Hyperlipidemias"[MeSH Terms] OR "Hyperlipidemias"[Title/Abstract] OR "Hyperlipidemic"[Title/Abstract] OR "Dyslipidemias"[Title/Abstract] OR "Dyslipidemic"[Title/Abstract] OR "Apolipoproteins"[MeSH Terms] OR "Apolipoprotein"[Title/Abstract] OR "Apolipoproteins"[Title/Abstract] OR "Apo"[Title/Abstract] OR "APOA"[Title/Abstract] OR "apolipoprotein A"[Title/Abstract] OR "lipoprotein a"[Title/Abstract] OR "lp a"[Title/Abstract] OR "Apolipoprotein A-1"[Title/Abstract] OR "Apolipoprotein A-I"[Title/Abstract] OR "Apo A2"[Title/Abstract] OR "Apolipoprotein A-II"[Title/Abstract] OR "apolipoproteins B"[Title/Abstract] OR "lp b"[Title/Abstract] OR "APOB"[Title/Abstract]) AND ("Intervention Studies"[Title/Abstract] OR "intervention"[Title/Abstract] OR "controlled trial"[Title/Abstract] OR "randomized"[Title/Abstract] OR "randomised"[Title/Abstract] OR "random"[Title/Abstract] OR "randomly"[Title/Abstract] OR "placebo"[Title/Abstract] OR "assignment"[Title/Abstract] OR "randomized controlled trial"[Title/Abstract] OR "randomized clinical trial"[Title/Abstract] OR "RCT"[Title/Abstract] OR "clinical trial"[Title/Abstract] OR "double blinded"[Title/Abstract] OR "trial"[Title/Abstract] OR "controlled clinical trial"[Title/Abstract] OR "Pragmatic clinical trial"[Title/Abstract] OR "crossover procedure"[Title/Abstract] OR "Cross-Over trial"[Title/Abstract] OR "Double-Blind Method"[Title/Abstract] OR "equivalence trial"[Title/Abstract]) | 350    |
| Scopus         | (( TITLE-ABS-KEY ( flax ) OR TITLE-ABS-KEY ( flaxseed ) OR TITLE-ABS-KEY ( "flax seed" ) OR TITLE-ABS-KEY ( "flax-seed" ) OR TITLE-ABS-KEY ( linseed ) OR TITLE-ABS-KEY ( lignan ) OR TITLE-ABS-KEY ( "whole flaxseed" ) OR TITLE-ABS-KEY ( "ground flaxseed" ) OR TITLE-ABS-KEY ( linseed ) OR TITLE-ABS-KEY ( "linum usitatissimum" ) OR TITLE-ABS-KEY ( linum ) OR TITLE-ABS-KEY ( "flaxseed oil" ) OR TITLE-ABS-KEY ( "linseed oil" ) OR TITLE-ABS-KEY ( "linum usitatissimum" ) OR TITLE-ABS-KEY ( "secoisolariciresinol diglucoside" ) ) ) AND (( TITLE-ABS-KEY ( "lipid profile" ) OR TITLE-ABS-KEY ( lipid ) OR TITLE-ABS-KEY ( lipids ) OR TITLE-ABS-KEY ( "blood lipids" ) OR TITLE-ABS-KEY ( lipoproteins ) OR TITLE-ABS-KEY ( lipoprotein ) OR TITLE-ABS-KEY ( abetalipoproteinemia ) OR TITLE-ABS-KEY ( cholesterol ) OR TITLE-ABS-KEY ( "total cholesterol" ) OR TITLE-ABS-KEY ( tc ) OR TITLE-ABS-KEY ( hypercholesterolemia ) OR TITLE-ABS-KEY ( hypercholesterolemic ) OR TITLE-ABS-KEY ( "high density lipoprotein" ) OR TITLE-ABS-KEY ( hdl ) OR TITLE-ABS-KEY ( hdl-c ) OR TITLE-ABS-KEY ( "tc/hdl ratio" ) OR TITLE-ABS-KEY ( hdl3 ) OR TITLE-ABS-KEY ( hdl2 ) OR TITLE-ABS-KEY ( idl ) OR TITLE-ABS-KEY ( "low density lipoprotein" ) OR TITLE-ABS-KEY ( "low density lipoprotein cholesterol" ) OR TITLE-ABS-KEY ( ldl ) OR TITLE-ABS-KEY ( "ldl cholesterol" ) OR TITLE-ABS-KEY ( ldl-c ) OR TITLE-ABS-KEY ( "cholesterol, ldl" ) OR TITLE-ABS-KEY ( vldl ) OR TITLE-ABS-KEY ( triglyceride ) OR TITLE-ABS-KEY ( triglycerides ) OR TITLE-ABS-KEY ( tg ) OR TITLE-ABS-KEY ( triacylglycerol ) OR TITLE-ABS-KEY ( tag ) OR TITLE-ABS-KEY ( hyperlipidemias ) OR TITLE-ABS-KEY ( hyperlipidemic ) OR TITLE-ABS-KEY ( dyslipidemias ) OR TITLE-ABS-KEY ( dyslipidemic ) OR TITLE-ABS-KEY ( "apolipoprotein" ) OR TITLE-ABS-KEY ( "apolipoproteins" ) OR TITLE-ABS-KEY ( apo ) OR TITLE-ABS-KEY ( apoa ) OR TITLE-ABS-KEY ( "apolipoprotein a" ) OR TITLE-ABS-KEY ( "lipoprotein (a)" ) OR TITLE-ABS-KEY ( "lp(a)" ) OR TITLE-ABS-KEY ( "apolipoprotein a-1" ) OR TITLE-ABS-KEY ( "apolipoprotein a-i" ) OR TITLE-ABS-KEY ( "apo a2" ) OR TITLE-ABS-KEY ( "apolipoprotein a-ii" ) OR TITLE-ABS-KEY ( "apolipoproteins b" ) OR TITLE-ABS-KEY ( "lp(b)" ) OR TITLE-ABS-KEY ( apob ) ) ) AND (( TITLE-ABS-KEY ( "intervention studies" ) OR TITLE-ABS-KEY ( intervention ) OR TITLE-ABS-KEY ( "controlled trial" ) OR TITLE-ABS-KEY ( randomized ) OR TITLE-ABS-KEY ( randomised ) OR TITLE-ABS-KEY ( random ) OR TITLE-ABS-KEY ( randomly ) OR TITLE-ABS-KEY ( placebo ) OR TITLE-ABS-KEY ( assignment ) OR TITLE-ABS-KEY ( "randomized controlled trial" ) OR TITLE-ABS-KEY ( "randomized clinical trial" ) OR TITLE-ABS-KEY ( rct ) OR TITLE-ABS-KEY ( "clinical trial" ) OR TITLE-ABS-KEY ( "double blinded" ) OR TITLE-ABS-KEY ( trial ) OR TITLE-ABS-KEY ( "controlled clinical trial" ) OR TITLE-ABS-KEY ( "pragmatic clinical trial" ) OR TITLE-ABS-KEY ( "crossover procedure" ) OR TITLE-ABS-KEY ( "cross-over trial" ) OR TITLE-ABS-KEY ( "double-blind method" ) OR TITLE-ABS-KEY ( "equivalence trial" ) ) )                                                                                                                                                                                         | 1149   |
| Web of Science | TS=(flax ) OR TS=(flaxseed ) OR TS=(“flax seed” ) OR TS=(“flax-seed” ) OR TS=(linseed ) OR TS=(lignan ) OR TS=(“whole flaxseed” ) OR TS=(“ground flaxseed” ) OR TS=(linseed ) OR TS=(“Linum usitatissimum” ) OR TS=(linum ) OR TS=(“flaxseed oil” ) OR TS=(“Linseed Oil” ) OR TS=(“Linum usitatissimum” ) OR TS=(“secoisolariciresinol diglucoside” AND TS=(“Lipid profile” ) OR TS=(lipid ) OR TS=(lipids ) OR TS=(“blood lipids” ) OR TS=(Lipoproteins ) OR TS=(Lipoprotein ) OR TS=(Abetalipoproteinemia ) OR TS=(Cholesterol ) OR TS=(“Total cholesterol” ) OR TS=(TC ) OR TS=(Hypercholesterolemia ) OR TS=(Hypercholesterolemic )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 974    |

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|  | OR TS=(“high density lipoprotein” ) OR TS=(HDL ) OR TS=(HDL-C ) OR TS=(“TC/HDL ratio” ) OR TS=(HDL3) OR TS=(HDL2) OR TS=(IDL ) OR TS=(“low density lipoprotein” ) OR TS=(“Low Density Lipoprotein Cholesterol” ) OR TS=(LDL ) OR TS=(“LDL Cholesterol” ) OR TS=(LDL-C ) OR TS=(“Cholesterol, LDL” ) OR TS=(VLDL ) OR TS=(triglyceride ) OR TS=(Triglycerides ) OR TS=(TG ) OR TS=(Triacylglycerol ) OR TS=(TAG ) OR TS=(Hyperlipidemias ) OR TS=(Hyperlipidemic ) OR TS=(Dyslipidemias ) OR TS=(Dyslipidemic ) OR TS=(Apolipoprotein ) OR TS=(Apolipoproteins ) OR TS=(Apo ) OR TS=(APOA ) OR TS=(“apolipoprotein A”) OR TS=(“lipoprotein (a)” ) OR TS=(“Lp(a)” ) OR TS=(“Apolipoprotein A-I” ) OR TS=(“Apolipoprotein A-I” ) OR TS=(“Apo A2” ) OR TS=(“Apolipoprotein A-II” ) OR TS=(“apolipoproteins B” ) OR TS=(“Lp(b)” ) OR TS=(APOB ) <b>AND</b> TS=(“Intervention Studies” ) OR TS=(intervention ) OR TS=(“controlled trial” ) OR TS=(randomized ) OR TS=(randomised ) OR TS=(random ) OR TS=(randomly ) OR TS=(placebo ) OR TS=(assignment ) OR TS=(“randomized controlled trial” ) OR TS=(“randomized clinical trial” ) OR TS=(RCT ) OR TS=(“clinical trial” ) OR TS=(“double blinded”) OR TS=(trial ) OR TS=(“controlled clinical trial” ) OR TS=(“Pragmatic clinical trial” ) OR TS=(“crossover procedure” ) OR TS=(“Cross-Over trial”) OR TS=(“Double-Blind Method”) OR TS=(“equivalence trial”) |  |
|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

## Appendix 2.

Supplemental Tables S2-S5. Subgroups analysis of impact of flaxseed on lipid parameters

S2. Subgroups analysis for TG

| Variables          | Durations             |                          | baseline             |                        | Health status        |                          | BMI                  |                         |                         |
|--------------------|-----------------------|--------------------------|----------------------|------------------------|----------------------|--------------------------|----------------------|-------------------------|-------------------------|
| TG                 | 12≤                   | <12                      | ≤150                 | 150<                   | Healthy              | Non-healthy              | Normal               | Overweight              | obese                   |
| No. of comparisons | 20                    | 17                       | 20                   | 16                     | 12                   | 25                       | 7                    | 19                      | 6                       |
| WMD (95%CI)        | -1.26(-11.14 to 8.62) | -16.86 (-28.56 to -5.16) | -1.79(-7.83 to 4.25) | -13.38(-30.01 to 3.23) | 1.72 (-3.31 to 6.71) | -14.58( -26.79 to -2.38) | -2.49(-8.09 to 3.09) | -10.57 (-25.67 to 4.52) | -18.29(-34.96 to -1.62) |
| p value            | 0.8                   | 0.005                    | 0.56                 | 0.11                   | 0.5                  | 0.01                     | 0.38                 | 0.17                    | 0.03                    |
| I <sup>2</sup> (%) | 83.87                 | 71.68                    | 61.43                | 78.13                  | 35.41                | 79.07                    | 0                    | 84.35                   | 84.45                   |
| P-heterogeneity    | <0.001                | <0.001                   | <0.001               | <0.001                 | 0.1                  | <0.001                   | 0.47                 | <0.001                  | <0.001                  |

S3. Subgroups analysis for TC

|                    | Variables          | Durations             | baseline            |                     | Health status         |                       | BMI                 |                      |                       |
|--------------------|--------------------|-----------------------|---------------------|---------------------|-----------------------|-----------------------|---------------------|----------------------|-----------------------|
| TC                 | 12≤                | <12                   | ≤ 200               | 200<                | Healthy               | Non-healthy           | Normal              | Overweight           | obese                 |
| No. of comparisons | 20                 | 19                    | 25                  | 13                  | 13                    | 26                    | 7                   | 20                   | 7                     |
| WMD<br>(95%CI)     | 0.31(-6.26 to 6.9) | -3.5 (-6.82 to -0.26) | -1.94(-7.5 to 3.63) | 0.99(-5.85 to 7.84) | -0.96 (-9.36 to 7.46) | -2.65( -3.68 to 4.82) | -2.7(-6.31 to 0.77) | -2.08(-6.86 to 2.68) | 0.09(-11.01 to 11.21) |
| p value            | 0.92               | 0.03                  | 0.49                | 0.77                | 0.82                  | 0.072                 | 0.12                | 0.39                 | 0.98                  |
| I <sup>2</sup> (%) | 88.56              | 0                     | 83.44               | 56.63               | 91.98                 | 0                     | 0                   | 38.5                 | 90.47                 |
| P-heterogeneity    | <0.001             | 0.8                   | <0.001              | 0.006               | <0.001                | 0.51                  | 0.55                | 0.04                 | <0.001                |

S4. Subgroups analysis for LDL

| Variables          | Durations           |                    | Baseline           |                      | Health status     |                      | BMI                 |                      |                     |
|--------------------|---------------------|--------------------|--------------------|----------------------|-------------------|----------------------|---------------------|----------------------|---------------------|
| LDL                | 12≤                 | <12                | ≤ 130              | 130<                 | Healthy           | Non-healthy          | Normal              | Overweight           | obese               |
| No. of comparisons | 19                  | 16                 | 26                 | 8                    | 11                | 24                   | 6                   | 19                   | 6                   |
| WMD<br>(95%CI)     | 1.04(-2.26 to 4.36) | 0.52 (-2.3 to 3.3) | 1.5(-1.15 to 4.16) | -3.36(-7.38 to 0.65) | 2.01 (-3 to 7.02) | 0.37( -1.82 to 2.56) | 3.02(-0.02 to 6.07) | -0.82 (-3.25 to 1.6) | 2.51(-3.35 to 8.59) |
| p value            | 0.53                | 0.71               | 0.26               | 0.1                  | 0.43              | 0.74                 | 0.052               | 0.5                  | 0.41                |
| I <sup>2</sup> (%) | 55.1                | 0                  | 41.49              | 0                    | 71.35             | 0                    | 0                   | 0                    | 70.9                |
| P-heterogeneity    | 0.002               | 0.54               | 0.015              | 0.78                 | <0.001            | 0.93                 | 0.46                | 0.47                 | 0.004               |

S5. Subgroups analysis for HDL

| Variables          | Durations           |                      | Baseline         |                      | Health status       |                       | BMI                 |                      |                     |
|--------------------|---------------------|----------------------|------------------|----------------------|---------------------|-----------------------|---------------------|----------------------|---------------------|
| HDL                | 12≤                 | <12                  | ≤ 40             | 40<                  | Healthy             | Non-healthy           | Normal              | Overweight           | obese               |
| No. of comparisons | 20                  | 18                   | 10               | 26                   | 13                  | 25                    | 7                   | 20                   | 7                   |
| WMD<br>(95%CI)     | -0.06(-2.1 to 1.96) | 0.33 (-1.44 to 2.11) | 1.35(0.3 to 2.4) | -0.02(-1.88 to 1.84) | 1.03(-3.02 to 5.09) | -0.31( -1.19 to 0.57) | 1.91(-1.75 to 4.99) | -0.35(-2.19 to 1.48) | -0.03(-3.7 to 3.64) |
| p value            | 0.94                | 0.71                 | 0.01             | 0.98                 | 0.61                | 0.48                  | 0.22                | 0.7                  | 0.98                |
| I <sup>2</sup> (%) | 84.47               | 54.3                 | 0                | 82.48                | 90.64               | 25.46                 | 58.37               | 76.99                | 89.36               |
| P-heterogeneity    | <0.001              | 0.003                | 0.62             | <0.001               | <0.001              | 0.12                  | 0.025               | <0.001               | <0.001              |

### Appendix 3.

Supplemental Table S6. Meta-regression for lipid parameters.

| Model                   | Fixed effect |                |         | Random effect |               |         |
|-------------------------|--------------|----------------|---------|---------------|---------------|---------|
| TG                      | slope        | 95%CI          | p value | slope         | 95%CI         | p value |
| Dose of supplementation | -0.65        | -1.62 to 0.31  | 0.18    | 0.44          | -1.17 to 2.06 | 0.59    |
| Intervention duration   | 0.86         | 0.57 to 1.16   | <0.001  | 1.51          | 0.44 to 2.57  | 0.0053  |
| TC                      |              |                |         |               |               |         |
| Dose of supplementation | -0.7         | -1.26 to -0.14 | 0.013   | 0.01          | -1.02 to 1.05 | 0.97    |
| Intervention duration   | 1.03         | 0.87 to 1.19   | <0.001  | 0.55          | 0.06 to 1.04  | 0.025   |
| LDL                     |              |                |         |               |               |         |
| Dose of supplementation | -0.41        | -0.94 to 0.12  | 0.12    | -0.19         | -0.82 to 0.44 | 0.55    |
| Intervention duration   | 0.46         | 0.27 to 0.66   | <0.001  | 0.44          | 0.22 to 0.66  | 0.0001  |
| HDL                     |              |                |         |               |               |         |
| Dose of supplementation | -0.21        | -0.43 to 0.004 | 0.055   | -0.03         | -0.38 to 0.32 | 0.85    |
| Intervention duration   | 0.14         | 0.05 to 0.23   | 0.002   | 0.033         | -0.21 to 0.27 | 0.78    |

Supplemental Table S6 Abbreviation: 95%CI: 95% confidence interval

## Appendix 4.

Supplemental Table S7. Assessment of publication bias in the impact of flaxseed on lipid parameters.


|            | Corrected effect size |                | Begg' rank correlation test |         | Egger's linear regression test |           |                |      |    | Fail safe N test |     |
|------------|-----------------------|----------------|-----------------------------|---------|--------------------------------|-----------|----------------|------|----|------------------|-----|
|            | WMD                   | 95% CI         | Kendall's Tau               | z-value | p-value                        | Intercept | 95% CI         | t    | df | p-value          | n   |
| <b>TG</b>  | -15.08                | -22.84 to -7.3 | 0.03                        | 0.27    | 0.78                           | -0.79     | -1.87 to 0.29  | 1.48 | 35 | 0.14             | 110 |
| <b>TC</b>  | -0.91                 | -5.49to 3.66   | 0.25                        | 2.32    | 0.02                           | -1.53     | -2.41 to -0.64 | 3.49 | 37 | 0.001            | 0   |
| <b>LDL</b> | 1.6                   | -0.83 to 4.04  | 0.07                        | 0.62    | 0.53                           | -0.72     | -1.41 to -0.03 | 2.14 | 33 | 0.039            | 0   |
| <b>HDL</b> | 1.88                  | 0.43 to 3.33   | -0.04                       | 0.4     | 0.68                           | 0.11      | -1.16to 1.39   | 0.18 | 36 | 0.85             | 0   |



A.TG



B.TC



C.LDL



**D.HDL**

Funnel Plot of Standard Error by Difference in means

